NVO   $107.21  -0.39% Market Closed After Close 107.25 0.04%

Novo Nordisk A/S
Last Events:

2023-09-20 The hottest instrument.

2023-08-09 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.

2023-08-09 Signal in MACD changed from bearish to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: down-crossing the middle level.

2023-08-09 Signal in RSI changed from bearish to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-09 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-09 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-08 The hottest instrument.

2023-08-06 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: signal line crossed the middle level.


Current temperature: 3.00
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 129.65
High with % probability:
Analyst Recommendations:
Number of estimates 9
Target Price Mean 144.48
Mean unverified/preliminary 144.48 / 144.48
Target Price Low / High 86.64 / 169.23
Median / STD DEV 157.07 / 199.91
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Buy ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None Sell None
stoch None None None
ma20 None ActivelyBuy ActivelyBuy
ma50 None None None
ma100 None None None
Candlestick PatternNov. 8, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US6701002056
ceo Mr. Lars Fruergaard Jorgensen
Website https://www.novonordisk.com
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.